{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-044409","form_type":"8-K","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2024-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.147091+00:00","generated_at":"2026-05-30T07:28:19.110754+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"C4 Therapeutics reports Q3 2024 revenue $15.4M; net loss narrows to $0.35/share","bullets":["Revenue rose to $15.4M (up 39% YoY) driven by an $8M Biogen milestone and $2.9M from Betta license.","Net loss improved to $24.7M from $27.0M YoY; diluted EPS of -$0.35 vs -$0.55.","Cash, equivalents and marketable securities $284.4M at Sep 30; expected runway into 2027.","Cemsidomide Phase 1/2 trial enrolling; MM and NHL data to be presented at ASH Dec 2024.","Appointed Paige Mahaney as Chief Scientific Officer; delivered second Biogen development candidate."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-044409","json":"https://secwatch.observer/filing/0001628280-24-044409.json","markdown":"https://secwatch.observer/filing/0001628280-24-044409.md","text":"https://secwatch.observer/filing/0001628280-24-044409.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000162828024044409/0001628280-24-044409-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000162828024044409/cccc-20241031.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T07:28:19.110754+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}